{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:50:26Z","timestamp":1761630626753},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,27]]},"DOI":"10.1097\/tp.0b013e31825def05","type":"journal-article","created":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T09:59:35Z","timestamp":1346234375000},"page":"603-611","source":"Crossref","is-referenced-by-count":35,"title":["Concurrent Acute Cellular Rejection Is an Independent Risk Factor for Renal Allograft Failure in Patients With C4d-Positive Antibody-Mediated Rejection"],"prefix":"10.1097","volume":"94","author":[{"given":"Marie","family":"Matignon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thangamani","family":"Muthukumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya V.","family":"Seshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manikkam","family":"Suthanthiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choli","family":"Hartono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1980.75","article-title":". Role of humoral presensitization in human renal transplant rejection.","volume":"17","author":"Gailiunas","year":"1980","journal-title":"Kidney Int"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1600-6143.2011.03525.x","article-title":". Summary of FDA antibody-mediated rejection workshop.","volume":"11","author":"Archdeacon","year":"2011","journal-title":"Am J Transplant"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2249.1991.tb02954.x","article-title":". Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection.","volume":"86","author":"Feucht","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/TP.0b013e3182483713","article-title":"A personal perspective: 100-year history of the humoral theory of transplantation.","volume":"93","author":"Terasaki","year":"2012","journal-title":"Transplantation"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-6143.2009.02987.x","article-title":". Banff 09 meeting report: antibody-mediated graft deterioration and implementation of Banff working groups.","volume":"10","author":"Sis","year":"2010","journal-title":"Am J Transplant"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/TP.0b013e318218e901","article-title":". Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.","volume":"91","author":"Walsh","year":"2011","journal-title":"Transplantation"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/ki.1993.187","article-title":". Capillary deposition of C4d complement fragment and early renal graft loss.","volume":"43","author":"Feucht","year":"1993","journal-title":"Kidney Int"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","article-title":". Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.","volume":"90","author":"Gaston","year":"2010","journal-title":"Transplantation"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1600-6143.2006.01686.x","article-title":". Determinants of poor graft outcome in patients with antibody-mediated acute rejection.","volume":"7","author":"Lefaucheur","year":"2007","journal-title":"Am J Transplant"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-6143.2009.02577.x","article-title":". Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.","volume":"9","author":"Everly","year":"2009","journal-title":"Am J Transplant"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":". Comparison of combination plasmapheresisIVIganti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00007890-200102270-00006","article-title":". Effect of histological damage on long-term kidney transplant outcome.","volume":"71","author":"Nankivell","year":"2001","journal-title":"Transplantation"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/TP.0b013e3181b723f4","article-title":". Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil.","volume":"88","author":"Rush","year":"2009","journal-title":"Transplantation"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":". Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/TP.0b013e3181cbac02","article-title":". Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection.","volume":"89","author":"Everly","year":"2010","journal-title":"Transplantation"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1600-6143.2009.02800.x","article-title":". De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure.","volume":"9","author":"Hidalgo","year":"2009","journal-title":"Am J Transplant"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0b013e3182139da1","article-title":". Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes.","volume":"91","author":"Cooper","year":"2011","journal-title":"Transplantation"},{"key":"R18-9-20210129","first-page":"318","article-title":". The impact of donor source, recipient age, pre-operative immunotherapy and induction therapy on early and late acute rejections in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).","volume":"2","author":"Tejani","year":"1998","journal-title":"Pediatr Transplant"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/01.TP.0000041722.34000.21","article-title":". Early versus late acute rejection episodes in renal transplantation.","volume":"75","author":"Sijpkens","year":"2003","journal-title":"Transplantation"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":". Rituximab therapy for acute humoral rejection after kidney transplantation.","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":". Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":". Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/ndt\/gfr465","article-title":". Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.","volume":"27","author":"Waiser","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":". A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0b013e31825def05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:28:31Z","timestamp":1620977311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201209270-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,27]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31825def05","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,27]]}}}